31 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... Disease in HIV-AIDS ... #Prophylaxis #Opportunistic ... Infections #OIs #HIVAIDS ... IDSA #management #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
First Episode of Opportunistic ... Disease in HIV-AIDS ... #Prophylaxis #Opportunistic ... Infections #OIs #HIVAIDS ... IDSA #management #pharmacology
Figure 1: Time Course of HIV Detection following Infection

#Diagnosis #InfectiousDiseases #HIVAIDS #Testing #Windows #Screening #Antibody #Detection
Time Course of HIV ... #Diagnosis #InfectiousDiseases ... #HIVAIDS #Testing
Blurry vision in a patient with HIV/AIDS
Anterior Segment:
 • Herpes zoster ophthalmicus
 • Keratitis (HSV, Staph,
a patient with HIV ... Acanthameoba, Candida ... Posterior Segment: • HIV ... Blurry #vision #HIVAIDS ... #InfectiousDiseases
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
known to have HIV ... 3 years • Co-testing ... Treatment #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
Candidiasis in HIV-AIDS ... #Candidiasis #candida ... Treatment #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
Preventing and Treating ... Infections in HIV-AIDS ... Treatment #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Preventing and Treating ... Infections in HIV-AIDS ... Treatment #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Leishmaniasis in HIV-AIDS ... Treating Visceral ... Treatment #management #opportunistic ... #infections #HIVAIDS ... #pharmacology
1,3 Beta-D-Glucan and Galactomannan - Pathogens, and Testing Characteristics
1,3 ß-D-glucan:
 • Most fungi excluding mucor and
Pathogens, and Testing ... Primarily studied for candida ... pneumonia, Plasmalyte (IV ... Galactomannan #Pathogens #Testing ... Specificity #Laboratory #InfectiousDiseases